Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly translated into clinical studies and have motivated drug development effort...

Descripción completa

Detalles Bibliográficos
Autores principales: Picaud, Sarah, Leonards, Katharina, Lambert, Jean-Philippe, Dovey, Oliver, Wells, Christopher, Fedorov, Oleg, Monteiro, Octovia, Fujisawa, Takao, Wang, Chen-Yi, Lingard, Hannah, Tallant, Cynthia, Nikbin, Nikzad, Guetzoyan, Lucie, Ingham, Richard, Ley, Steven V., Brennan, Paul, Muller, Susanne, Samsonova, Anastasia, Gingras, Anne-Claude, Schwaller, Juerg, Vassiliou, George, Knapp, Stefan, Filippakopoulos, Panagis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061470/
https://www.ncbi.nlm.nih.gov/pubmed/27757418
http://dx.doi.org/10.1126/sciadv.1600760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061470/
https://www.ncbi.nlm.nih.gov/pubmed/27757418
http://dx.doi.org/10.1126/sciadv.1600760

Ejemplares similares